Market Cap: $94.2M
Market Cap: $94.2M
Open
$3.63
Prev. Close
$0.9238
High
$3.77
Low
$3.58
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices.
Perspective Therapeutics, Inc. trades on the New York Stock Exchange Arca under the ticker CATX, priced in USD.
Perspective Therapeutics, Inc. has a market capitalisation of $94.2M, based on its latest share price.
Over the past 52 weeks CATX has traded between $0.7795 and $6.16.
No. Perspective Therapeutics, Inc. does not currently pay a dividend.
Not yet. Perspective Therapeutics, Inc. is a pre-revenue company, so losses are expected while it develops its business. Cash on hand covers about 1.5 years of spending at the current burn rate.
The analyst consensus rating for CATX is Buy. Analysts' average 12-month price target of $10.33 implies 1224% upside.
Johan Spoor is the CEO of Perspective Therapeutics, Inc., which is headquartered in Seattle.
Generated automatically from reported financial data. General information only, not financial advice.
Nuclear supply boost seen as support for life‑sciences manufacturing Denison Mines wins final federal approval from the Canadian Nuclear Safety Commission to prepare the site and construct the Phoenix…
Delivery-Driven Oncology Boom Shapes Prospects for Perspective Therapeutics Perspective Therapeutics is positioned amid a swift shift in oncology toward smarter delivery systems and novel modalities t…
Perspective Therapeutics positions itself amid a push for smarter delivery systems in oncology Perspective Therapeutics is named among a cohort of companies navigating a rapid shift in oncology toward…
NexTech Solutions Enhances ISR Capabilities with Acquisition of Vidterra NexTech Solutions (NTS) recently announces its acquisition of Vidterra, a key player in edge-deployed video distribution softwa…